The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The potential of NK cell-based therapies for B-cell lymphomas
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the potential of NK cell-based therapies for B-cell lymphomas. Dr Patel notes that while these therapies have not yet achieved broad availability, a recent study demonstrates the proof of principle for their development as a rapid and effective cellular therapy approach. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we know cellular therapy has a huge role to play in B-cell lymphomas. One of the challenges we have is the timeliness of delivery. So we’ve been looking to develop allogeneic products for some time now. I think one area that really remains still interesting, we haven’t quite seen the successes that we need, are NK cell-based therapies. These offer very different toxicity profiles, so very little CRS, almost no ICANS, and we can make really a large number of cells from induced pluripotent stem cells...
So we know cellular therapy has a huge role to play in B-cell lymphomas. One of the challenges we have is the timeliness of delivery. So we’ve been looking to develop allogeneic products for some time now. I think one area that really remains still interesting, we haven’t quite seen the successes that we need, are NK cell-based therapies. These offer very different toxicity profiles, so very little CRS, almost no ICANS, and we can make really a large number of cells from induced pluripotent stem cells. So I think this technology, while it hasn’t quite made it to broad availability, that study demonstrates really, I think, the proof of principle that this is another avenue of cellular therapy that’s really important to develop for rapid deployment and broader deployment of cellular therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
